Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3090051 | 0.83 | SIGMAR1 (0.58) | SIGMAR1CHRM2CHRM1 | |
| SCHEMBL29483945 | 0.81 | SIGMAR1 (0.56) | SIGMAR1CHRM2CHRM1 | |
| SCHEMBL3100817 | 0.81 | SIGMAR1 (0.56) | SIGMAR1CHRM2CHRM1 | |
| SCHEMBL4599654 | 0.81 | SIGMAR1 (0.56) | SIGMAR1CHRM2CHRM1 | |
| SCHEMBL8736360 | 0.81 | SIGMAR1 (0.56) | SIGMAR1CHRM2CHRM1MCHR1 | |
| SCHEMBL4599655 | 0.81 | SIGMAR1 (0.56) | SIGMAR1CHRM2CHRM1 | |
| SCHEMBL15080727 | 0.81 | SIGMAR1 (0.56) | SIGMAR1CHRM2CHRM1 | |
| SCHEMBL6488211 | 0.80 | SIGMAR1 (0.55) | SIGMAR1CHRM2CHRM1 | |
| SCHEMBL3106101 | 0.80 | SIGMAR1 (0.55) | SIGMAR1CHRM2CHRM1 | |
| SCHEMBL29483935 | 0.79 | SIGMAR1 (0.54) | SIGMAR1CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550467-B2 | Bicyclic compounds as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders | SCHERING CORPORATION (US) | 2009-06-23 | — | — | US | disclosed |
| EP-1807409-A2 | BICYCLIC COMPOUNDS AS SELECTIVE MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OBESITY AND RELATED DISORDERS | Pharmacopeia Drug Discovery, Inc. (US) | 2007-07-18 | — | — | EP | disclosed |
| US-20060111360-A1 | Bicyclic compounds as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders | PHARMACOPEIA DRUG DISCOVERY, INC. | 2006-05-25 | — | — | US | disclosed |
| WO-2006044293-A2 | BICYCLIC COMPOUNDS AS SELECTIVE MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OBESITY AND RELATED DISORDERS | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111360-A1 | Bicyclic compounds as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders | MCHR1, MCHR2, MC4R | SIGMAR1 155/4885CHRM2 152/4885CHRM1 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.